Merck receives approval for Alzheimer’s label claim for insomnia drug

Merck & Co/MSD has claimed FDA approval for a new use of its insomnia drug Belsomra, treating sleep disruption in people with mild-to-moderate Alzheimer’s disease. Belsomra (suvorexant) has been approved since 2014 for treating insomnia in the general population characterised by difficulties with falling or staying asleep, becoming the first in a new class of drugs targeting

Continue Reading

Projects examines FDA approved drugs for Alzheimer’s leads to concerns over research

It has been quite a disappointing period recently for researching Alzheimer’s disease treatments in the last week, after Pfizer announced it would be shutting its neuroscience division and Axovant’s drug candidate flopped. This recent activity has led to serious fears over the development of potential treatments in the future, as companies become increasingly cautious over

Continue Reading